MYGN

Myriad Genetics Inc. 10-Q Summary

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for Myriad Genetics, Inc., a biotechnology company focused on predictive medicine and therapeutic drug development. The report covers the quarterly and six-month periods ended December 31, 2005. The company operates three segments: Research, Predictive Medicine, and Drug Development.

Key Financial Metrics

Segment Performance (6 Months Ended Dec 31, 2005):

• Predictive Medicine: Revenue of $44.9 million; Operating Income of $13.9 million. Gross margin improved to 73%.
• Research: Revenue of $7.5 million; Operating Loss of $(6.3) million.
• Drug Development: No revenue; Operating Loss of $(27.3) million.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 39% for the three months and 44% for the six months compared to the prior year periods. Predictive medicine revenue grew 33% (quarterly) and 41% (six-month), driven by wider medical acceptance and marketing efforts. Research revenue surged 87% (quarterly) and 72% (six-month) due to data delivery from collaborations.
• Expense Increases: R&D expenses rose 31% (quarterly) and 35% (six-month) due to expanded clinical trials (specifically Flurizan) and drug discovery programs. SG&A expenses increased 9% in both periods to support business growth.
• Liquidity Expansion: Cash and marketable securities increased by $121.3 million (106%) from June 30, 2005, primarily due to a public offering of common stock in November 2005 yielding $139.7 million in net proceeds.
• Loss Reduction: Net loss decreased to $7.95 million for the quarter (from $10.05 million) and $17.2 million for the six months (from $20.0 million), despite higher operating expenses, aided by increased interest income ($1.65 million vs $0.69 million quarterly).

Guidance, Outlook, and Risks

Outlook: Management expects to incur losses for at least the next several years due to the expansion of drug discovery, clinical trials, and facility expansion. The company believes its current capital resources are sufficient to fund operations for at least the next two years.

Key Developments:

• Flurizan (Alzheimer's): Phase 3 trial initiated for mild Alzheimer's; Phase 2 follow-on ongoing. Phase 2b trial for prostate cancer is underway.
• Pipeline: MPC-6827 (solid tumors/brain metastases) and MPC-2130 (blood cancers) are in Phase 1 trials. MPI-49839 (AIDS) and MPC-0920 (thrombosis) are in late-stage preclinical development.
• Accounting Changes: The company adopted FASB Statement No. 123R (Share-Based Payment) effective July 1, 2005, resulting in the recognition of share-based compensation expense ($729,000 for the six months ended Dec 31, 2005).

Risks: Significant risks include the failure of clinical trials (specifically Flurizan), inability to secure regulatory approval, competition, patent infringement claims, and the need for additional financing if capital resources are consumed faster than anticipated.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $235.1 million in liquid assets (cash + marketable securities) against the projected burn rate for ongoing Phase 3 trials.
• Flurizan Trial Progress: Monitor enrollment and interim data for the Phase 3 Alzheimer's trial and Phase 2b prostate cancer trial, as these are critical to future valuation.
• Predictive Medicine Margins: Confirm the sustainability of the 73% gross margin in the predictive medicine segment amidst potential pricing pressures or increased royalty obligations.
• Share-Based Compensation: Review the impact of the new FASB 123R standard on future net loss, noting $5.2 million of unrecognized compensation cost remaining.
• Stock Offering Dilution: Assess the impact of the 8.05 million shares issued in November 2005 on future earnings per share.